Ginkgo Bioworks Holdings, Inc. DNA
Our mission is to make biology easier to engineer. That has never changed. Every choice we've made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
1.Biology is programmable. All living things run on the same DNA code.
2.Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day.
3.Biology is hard. Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M | — |
| R&D | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M | — |
| SG&A | $183.3M | $246.2M | $385.0M | $1.43B | $863.0M | $38.3M | $29.5M | — |
| Total operating expenses | $485.4M | $786.8M | $1.12B | $2.69B | $2.14B | $213.7M | $125.8M | — |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.21B | -$1.83B | -$137.0M | -$71.6M | — |
| Interest expense | $0 | $94.0K | $93.0K | $106.0K | $2.4M | $2.4M | $2.4M | — |
| Pre-tax income | -$313.6M | -$547.5M | -$892.9M | -$2.12B | -$1.84B | -$124.8M | -$119.8M | — |
| Income tax | $837.0K | $479.0K | $71.0K | $15.0M | $1.5M | $1.9M | $22.0K | — |
| Net income | -$313.0K | -$547.0K | -$893.0K | -$2.1M | -$1.8M | -$126.6M | -$119.3M | — |
| EPS, basic | -5.64 | -10.54 | -18.37 | -50.15 | -1.35 | -0.10 | -0.10 | — |
| EPS, diluted | -5.64 | -10.54 | -18.37 | -50.20 | -1.39 | -0.10 | -0.10 | — |
| Shares, diluted (wtd. avg.) | $55.5M | $51.9M | $48.6M | $42.0M | $1.36B | $1.27B | $1.15B | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $167.2M | $561.6M | $944.1M | $1.32B | $1.55B | $380.8M | $495.3M | $207.4M |
| Short-term investments | $255.4M | $0 | — | — | — | — | — | — |
| Receivables | $24.0M | $21.9M | $17.2M | $80.9M | $131.5M | $16.7M | — | — |
| Inventory | — | — | $46.0K | $4.4M | $3.4M | $2.7M | — | — |
| Total current assets | $471.8M | $602.7M | $1.00B | $1.45B | $1.72B | $426.5M | — | — |
| Property, plant and equipment | $167.8M | $203.7M | $188.2M | $314.8M | $145.8M | $121.4M | — | — |
| Goodwill | — | $0 | $49.2M | $60.2M | $21.3M | $1.9M | $1.9M | — |
| Other intangibles | $56.9M | $72.5M | $82.7M | $111.0M | $21.6M | $3.3M | — | — |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675.2M | — | — |
| Accounts payable | $10.6M | $14.2M | $9.3M | $10.5M | $8.2M | $13.9M | — | — |
| Total current liabilities | $96.0M | $107.3M | $163.9M | $173.0M | $134.8M | $73.2M | — | — |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M | $205.1M | — | — |
| Retained earnings | -$6.15B | -$5.84B | -$5.29B | -$4.40B | -$2.30B | -$467.9M | — | — |
| Total equity | $508.6M | $716.1M | $1.10B | $1.74B | $1.57B | $470.1M | $501.9M | $213.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M | -$135.8M | -$44.7M | — |
| Depreciation and amortisation | $40.3M | $45.0M | $54.8M | $36.9M | $26.9M | $12.6M | $9.6M | — |
| Stock-based compensation | $81.5M | $112.3M | $229.9M | $1.93B | $1.61B | $476.0K | $771.0K | — |
| Capital expenditure | $7.7M | $62.5M | $40.8M | $52.3M | $56.5M | $57.8M | $22.2M | — |
| Investing cash flow | -$240.3M | -$62.2M | -$80.7M | -$67.4M | -$73.3M | -$67.1M | -$74.6M | — |
| Financing cash flow | $17.8M | -$1.7M | -$3.2M | $95.3M | $1.53B | $90.3M | $410.4M | — |
| Buybacks | — | — | — | — | — | — | $408.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028377.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |